QMS Medi Approves Composite Scheme of Arrangement and Acquisition of BeamOptics
QMS Medical Allied Services Limited's board approved a composite scheme of arrangement to merge its healthcare services with HCAH into Saarathi Healthcare. Additionally, QMS will acquire 100% of BeamOptics Scientific Private Limited, with the consideration to be determined by a valuation report. The acquisition is expected to complete by November 30, 2027.
The composite scheme of arrangement involving multiple entities and the acquisition of another company are significant strategic moves that could materially alter the company's structure, operations, and market position.
The company is undertaking a significant restructuring and acquisition, which is generally viewed positively as it aims to drive focused growth, operational efficiencies, and expand its addressable market.
QMS Medical Allied Services Limited announced a significant composite scheme of arrangement involving QMS, Health Care at Home India Private Limited (HCAH), and Saarathi Healthcare Private Limited (Saarathi). The scheme aims to combine the healthcare services business of QMS and HCAH into Saarathi, which will then seek listing on the National Stock Exchange of India Limited. The demerged undertaking of QMS had a turnover of ₹37.17 crore in the fiscal year ended March 31, 2026, representing 24.41% of its total turnover.
In conjunction with the scheme, QMS also approved the execution of a merger co-operation agreement and a shareholders' agreement among various parties, including its promoter, Mr. Mahesh Makhija, and investment entities. Furthermore, QMS has entered into a binding Memorandum of Understanding to acquire 100% of the equity shares of BeamOptics Scientific Private Limited. The consideration for this acquisition will be determined based on an independent valuation report, with an indicative completion period by November 30, 2027. BeamOptics Scientific Private Limited, incorporated in October 2023, had a turnover of ₹113.81 Lakhs in FY2025-2026 and operates in the Healthcare Products & Technology sector.
The Board of Directors meeting, held on September 25, 2026, from 3:15 PM to 3:50 PM IST, also approved these significant corporate actions. The scheme is subject to approvals from shareholders, creditors, the National Company Law Tribunal (NCLT), and stock exchanges.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under merger. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.